Efficacy and safety of coenzyme A versus fenofibrate in patients with hyperlipidemia: a multicenter, double-blind, double-mimic, randomized clinical trial

References

• Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115(4):450–458.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102(10):1Ke34K–1Ke34K.
   Web of Science ®Google Scholar
• Ferrari R, Aguiar C, Alegria E, et al. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. Eur Heart J Suppl. 2016;18(Suppl C):C2–C12.
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849e61. [Erratum in: Lancet 2006;368:1415].
   Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410–418.
   PubMed Web of Science ®Google Scholar
• Scott R, O’Brien R, Fulcher G, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32(3):493–498.
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Eng J Med. 2010;362:1563–1574.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363:692–684.
   PubMed Web of Science ®Google Scholar
• Chen YQ, Zhao SP, Chen JZ, et al. The effects of coenzyme A on serum lipids in patients with hyperlipidemia: results of a multicenter clinical trial. J Clin Endocrinol Metab. 2013;98(2):E275–E278.
   PubMed Web of Science ®Google Scholar
• Chen YQ, Zhao SP, Zhao YH. Efficacy and tolerability of coenzyme A vs pantethine for the treatment of patients with hyperlipidemia: a randomized, double-blind, multicenter study. J Clin Lipidol. 2015;9(5):692–697.
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection: Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol. 2013;10(8):453–464.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(11):1345–1361.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017;14(7):401–411.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Colletti A, Bajraktari G, et al. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. 2017;75(9):731–767.
   Google Scholar
• Banach M, Patti AM, Giglio RV, et al. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel The Role of Nutraceuticals in Statin Intolerant Patients. J Am Coll Cardiol. 2018;372(1):96–11.
   PubMed Web of Science ®Google Scholar
• Consolo F, Di Tommaso G, Arrigo F, et al. Action of coenzyme A on changes in the blood lipid pattern after administration of dietary lipids. Boll Soc Ital Biol Sper. 1975;51:1931–1936.
   PubMedGoogle Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
   PubMed Web of Science ®Google Scholar
• Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 – executive summary. J Clin Lipidol. 2014;8(5):473–488.
   PubMed Web of Science ®Google Scholar
• Siniawski DA, Masson W, Lobo M, et al. Association between changes in LDL-C, non-HDL cholesterol, apolipoprotein B levels and coronary plaque regression. J Clin Lipidol. 2014;8(3):318–319.
   Google Scholar
• Lin FJ, Tseng WK, Yin WH, et al. Residual risk factors to predict major adverse cardiovascular events in atherosclerotic cardiovascular disease patients with and without diabetes mellitus. Sci Rep. 2017;7(1):9179.
   Google Scholar
• Liu J, Sempos C, Donahue RP, et al. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care. 2005;28(8):1916–1921.
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–1818.
   PubMed Web of Science ®Google Scholar
• Barnes PM, Powell-Griner E, McFann K, et al. Complementary and alternative medicine use among adults: United States 2002. Adv Data. 2004;343:1–19.
   PubMedGoogle Scholar
• Aguiar C, Alegria E, Bonadonna RC, et al. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: a report from an expert consensus meeting on the role of fenofibrate–statin combination therapy. Atheroscler Suppl. 2015;19:1–12.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Assessment report for fenofibrate, beza-fibrate, ciprofibrate, and gemfibrozil containing medical products. 2011 Feb 28.
   Google Scholar
• Lai J, Wu B, Xuan T, et al. Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-blind, randomized, placebo-controlled study. Lipids Health Dis. 2014;13(1):1.
   PubMed Web of Science ®Google Scholar